Abstract
During ALL chemotherapy, a 4-year-old patient presented with febrile neutropenia and abdominal pain. Ultrasound examinations were repeatedly normal. Computerized tomography on day 7 demonstrated appendicitis and multiple hepatic foci identified as mucormycosis (Absidia corymbifera). Successful outcome was achieved by aggressive re-surgery, long-term antifungal therapy with serum level-monitored posaconazole, and recovery of neutrophil counts. Considering the interference of posaconazole with CYP3A4, vincristine was administered during 72 hr posaconazole windows. Pediatric intestinal mucormycosis, still associated with a >70% case-fatality rate, calls for early imaging and surgery to establish the diagnosis, reduce the fungal mass, and provide a rationale for using posaconazole.
(c) 2009 Wiley-Liss, Inc.
MeSH terms
-
Antifungal Agents / therapeutic use
-
Antineoplastic Agents, Phytogenic / therapeutic use
-
Child, Preschool
-
Drug Therapy, Combination
-
Humans
-
Immunocompromised Host*
-
Intestinal Diseases / diagnostic imaging
-
Intestinal Diseases / drug therapy*
-
Intestinal Diseases / microbiology
-
Liver Diseases / diagnostic imaging
-
Liver Diseases / drug therapy*
-
Liver Diseases / microbiology
-
Magnetic Resonance Imaging
-
Male
-
Mucormycosis / diagnostic imaging
-
Mucormycosis / drug therapy*
-
Mucormycosis / microbiology
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology
-
Tomography, X-Ray Computed
-
Triazoles / therapeutic use
-
Vincristine / therapeutic use
Substances
-
Antifungal Agents
-
Antineoplastic Agents, Phytogenic
-
Triazoles
-
Vincristine
-
posaconazole